HK1225298A1 - Cd6結合配對體的使用和以其為基礎的方法 - Google Patents

Cd6結合配對體的使用和以其為基礎的方法

Info

Publication number
HK1225298A1
HK1225298A1 HK16113658A HK16113658A HK1225298A1 HK 1225298 A1 HK1225298 A1 HK 1225298A1 HK 16113658 A HK16113658 A HK 16113658A HK 16113658 A HK16113658 A HK 16113658A HK 1225298 A1 HK1225298 A1 HK 1225298A1
Authority
HK
Hong Kong
Prior art keywords
method based
binding partner
partner
binding
Prior art date
Application number
HK16113658A
Other languages
English (en)
Inventor
Pradip Nair
Ramakrishnan Melarkode
Bala S Manian
Abhijit Barve
Usha Bughani
Casimiro Jose Enrique Montero
Original Assignee
Biocon Ltd
Centro De Inmunolgia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocon Ltd, Centro De Inmunolgia Molecular filed Critical Biocon Ltd
Publication of HK1225298A1 publication Critical patent/HK1225298A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
HK16113658A 2013-07-23 2016-11-30 Cd6結合配對體的使用和以其為基礎的方法 HK1225298A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3264CH2013 2013-07-23

Publications (1)

Publication Number Publication Date
HK1225298A1 true HK1225298A1 (zh) 2017-09-08

Family

ID=52392806

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16113658A HK1225298A1 (zh) 2013-07-23 2016-11-30 Cd6結合配對體的使用和以其為基礎的方法

Country Status (15)

Country Link
US (3) US10189899B2 (zh)
EP (3) EP3936148A1 (zh)
JP (4) JP6530391B2 (zh)
KR (3) KR102276745B1 (zh)
AR (1) AR097038A1 (zh)
AU (3) AU2014294616B2 (zh)
CA (1) CA2920368C (zh)
DK (1) DK3024485T3 (zh)
ES (1) ES2843683T3 (zh)
HK (1) HK1225298A1 (zh)
NZ (1) NZ746944A (zh)
PL (1) PL3024485T3 (zh)
PT (1) PT3024485T (zh)
TW (1) TW201511772A (zh)
WO (1) WO2015011658A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA104587C2 (ru) 2008-03-14 2014-02-25 Биокон Лимитед Моноклональное антитело и способ его применения
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
EP3528846A4 (en) * 2016-10-18 2020-06-03 Biocon Limited USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
AU2019295855A1 (en) * 2018-06-29 2021-01-28 City Of Hope CD6 targeted chimeric antigen receptors for treatent of certain autoimmune disorders
WO2022067240A1 (en) * 2020-09-28 2022-03-31 Vor Biopharma, Inc. Compositions and methods for cd6 modification

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US699755A (en) 1902-03-06 1902-05-13 Ira G Hoag Train-order box in connection with semaphores.
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
EP0631783A1 (en) 1993-06-03 1995-01-04 Mitsubishi Chemical Corporation Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives
AU703694B2 (en) 1993-11-02 1999-04-01 Bristol-Myers Squibb Company CD6 ligand
US5998172A (en) 1993-11-02 1999-12-07 Duke University Anti-CD6 ligand antibodies
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
WO1996023879A1 (en) 1995-01-30 1996-08-08 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
ATE207889T1 (de) 1996-03-20 2001-11-15 Aventis Pharma Sa Trizyclische verbindungen mit wirkung auf integrine, besonders auf das alphavbeta3-integrin,verfahren zur ihrer herstellung und zwischenprodukte des verfahrens, ihre verwendung als arzneimittel und sie enthaltende pharmazeutische zusammensetzungen
JP2001523956A (ja) 1997-03-03 2001-11-27 ブリストル−マイヤーズ・スクイブ・カンパニー ヒトｃｄ６に対するモノクローナル抗体
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
WO2000058362A1 (en) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Neutrokine-alpha binding proteins and methods based thereon
AU777970C (en) 1999-05-07 2006-08-17 F. Hoffman-La Roche Ag Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
AU2001250814B2 (en) 2000-03-16 2007-02-15 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
JP2003534022A (ja) 2000-05-26 2003-11-18 スミスクライン・ビーチャム・コーポレイション Ｒａｎｋリガンド介在障害の治療に有用な抗−ｒａｎｋリガンドモノクローナル抗体
ES2192128B1 (es) 2001-04-27 2005-01-01 Universidad De Vigo Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
WO2003009817A2 (en) 2001-07-25 2003-02-06 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
LT2335725T (lt) 2003-04-04 2017-01-25 Genentech, Inc. Didelės koncentracijos antikūno ir baltymo kompozicijos
EP2168986A3 (en) 2004-02-19 2010-07-28 Genentech, Inc. CDR-repaired antibodies
EA010350B1 (ru) * 2004-06-03 2008-08-29 Новиммун С.А. Антитела против cd3 и способы их применения
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
JP2008528638A (ja) 2005-01-28 2008-07-31 ワイス ポリペプチドの安定化液体処方
KR20140077946A (ko) 2005-10-13 2014-06-24 휴먼 게놈 사이언시즈, 인코포레이티드 자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
KR20090021298A (ko) 2006-06-14 2009-03-02 임클론 시스템즈 인코포레이티드 항-ｅｇｆｒ 항체의 동결건조 제제
AU2007331712A1 (en) 2006-12-11 2008-06-19 F. Hoffmann-La Roche Ag Abeta antibody parenteral formulation
CN101199483B (zh) 2006-12-14 2011-01-26 上海中信国健药业股份有限公司 一种稳定的抗her2人源化抗体制剂
CN101678101B (zh) 2006-12-26 2012-11-07 分子免疫中心 可用于诊断和治疗b细胞慢性淋巴细胞白血病的能够在肿瘤细胞中诱导凋亡的药物组合物
ES2785043T3 (es) 2006-12-26 2020-10-05 Ct Inmunologia Molecular Composición farmacéutica, que comprende un anticuerpo monoclonal anti-cd6 usado en el diagnóstico y tratamiento de la artritis reumatoide
CN101600457B (zh) 2007-01-09 2014-01-08 惠氏公司 抗il-13抗体调配物和其用途
JP2010111581A (ja) * 2007-01-25 2010-05-20 Imuno:Kk ドーパミンｄ２様受容体アゴニストを有効成分とする医薬及びスクリーニング方法
CN101675076B (zh) * 2007-02-28 2013-09-18 默沙东公司 工程化的抗il-23r抗体
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US7951368B2 (en) 2007-06-25 2011-05-31 Amgen Inc. Compositions of specific binding agents to hepatocyte growth factor
WO2009037190A2 (en) 2007-09-21 2009-03-26 F. Hoffmann-La Roche Ag Pharmaceutical formulation for il-ir antibody
EP2238241B1 (en) * 2008-01-18 2013-09-11 The Brigham and Women's Hospital, Inc. Selective differentiation, identification, and modulation of human th17 cells
UA104587C2 (ru) * 2008-03-14 2014-02-25 Биокон Лимитед Моноклональное антитело и способ его применения
DK3721904T3 (da) 2009-11-20 2021-11-15 Biocon Ltd Formuleringer af t1h-antistof
GB201013975D0 (en) * 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
US9216988B2 (en) * 2011-12-22 2015-12-22 Genentech, Inc. Benzyl sulfonamide derivatives as RORc modulators
CN102559636B (zh) 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
KR102276745B1 (ko) 2013-07-23 2021-07-14 바이오콘 리미티드 Cd6 결합 파트너의 용도 및 이에 기초한 방법
EP3528846A4 (en) 2016-10-18 2020-06-03 Biocon Limited USE OF ITOLIZUMAB TO REDUCE PHOSPHORYLATION OF CD6
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
SG11202008149RA (en) 2018-02-27 2020-09-29 Equillium Inc Anti cd6 antibodies for treating severe asthma

Also Published As

Publication number Publication date
JP7221264B2 (ja) 2023-02-13
KR102034757B1 (ko) 2019-10-21
JP6868655B2 (ja) 2021-05-12
US20190345247A1 (en) 2019-11-14
EP3024485B1 (en) 2020-11-18
JP2022145689A (ja) 2022-10-04
US20160152705A1 (en) 2016-06-02
AU2021240292A1 (en) 2021-10-28
KR102405247B1 (ko) 2022-06-07
AU2019246781B2 (en) 2021-07-01
AU2014294616A1 (en) 2016-02-18
NZ746944A (en) 2021-07-30
KR20160033786A (ko) 2016-03-28
KR20210088739A (ko) 2021-07-14
DK3024485T3 (da) 2020-12-07
CA2920368C (en) 2023-03-21
AR097038A1 (es) 2016-02-17
JP2019112446A (ja) 2019-07-11
EP3738613A1 (en) 2020-11-18
EP3024485A4 (en) 2017-03-08
JP6530391B2 (ja) 2019-06-12
JP2021038266A (ja) 2021-03-11
KR20190120426A (ko) 2019-10-23
PL3024485T3 (pl) 2021-06-14
EP3024485A1 (en) 2016-06-01
JP2016525538A (ja) 2016-08-25
WO2015011658A1 (en) 2015-01-29
US10189899B2 (en) 2019-01-29
KR102276745B1 (ko) 2021-07-14
AU2014294616B2 (en) 2019-07-11
EP3936148A1 (en) 2022-01-12
US11028168B2 (en) 2021-06-08
TW201511772A (zh) 2015-04-01
NZ716381A (en) 2021-06-25
CA2920368A1 (en) 2015-01-29
PT3024485T (pt) 2021-01-25
US20220025038A1 (en) 2022-01-27
ES2843683T3 (es) 2021-07-20
AU2019246781A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
GB2519633B (en) Driveline and method of controlling a driveline
HUE053410T2 (hu) Alkalmazási eljárás és alkalmazási berendezés
PT2999103T (pt) Conversor e respetivo método de controlo
EP3065456A4 (en) USER DEVICE AND METHOD
IL246235A0 (en) A method for the production of adenoviruses and corresponding plasmids
HK1226190A1 (zh) 擴音器附件和擴音器的使用方法
HK1209475A1 (zh) 閥及操作閥的方法
HK1225298A1 (zh) Cd6結合配對體的使用和以其為基礎的方法
GB201310643D0 (en) A browser plug-in and a method of operating a browser plug-in
HK1205214A1 (zh) 鑽土設備及鑽土方法
GB201305414D0 (en) Method and composition
GB201317313D0 (en) Lockerbank network and method of operation
GB201300376D0 (en) Method and compound
GB2521735B (en) Driveline and method of controlling a driveline
HK1220932A1 (zh) 用戶界面和用戶界面的操作方法
ZA201506677B (en) Firelog and method of making a firelog
GB201320359D0 (en) Assembly and method
GB201316134D0 (en) Stocking and Method
GB201308285D0 (en) Method and document
EP3084097B8 (en) A construction and a method of making a construction
GB2522839B (en) Method and document
PL3041506T3 (pl) Sposób leczenia
GB201315292D0 (en) Compound and method
GB201315296D0 (en) Compound and method
GB201315295D0 (en) Compound and method